Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 10/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960108 | 0.94 | ABL1 (0.48) | SMYD3MCHR1ABL1NPC1RAB9A | |
| SCHEMBL24960094 | 0.80 | NPC1 (0.48) | SMYD3ABL1HPGDNPC1RAB9A | |
| SCHEMBL24958916 | 0.77 | ABL1 (0.53) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24956358 | 0.75 | NPC1 (0.56) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24956359 | 0.75 | NPC1 (0.52) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24958860 | 0.75 | ABL1 (0.45) | SMYD3ABL1HPGDNPC1RAB9A | |
| SCHEMBL24958859 | 0.74 | GAA (0.49) | SMYD3ABL1HPGDNPC1RAB9A | |
| SCHEMBL9908373 | 0.74 | SMYD3 (0.56) | SMYD3NPC1RAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL25912472 | 0.74 | DPP4 (0.47) | SMYD3MCHR1ABL1NPC1RAB9A | |
| SCHEMBL24959359 | 0.73 | SIRT6 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | SMYD3 3180/4885MCHR1 445/4885ABL1 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.